{"product_id":"dhr-marketing-mix","title":"Danaher Corporation (DHR): Marketing Mix Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Danaher Corporation marketing mix analysis gives you a practical, research-based view of how the business sells recurring consumables, instruments, and services through global B2B channels as of late 2025. You’ll quickly see the core product mix, global life sciences and diagnostics reach, China bioprocessing demand, North American academic research exposure, biopharma reshoring tailwinds, promotion through product launches, FDA clearance messaging and partnerships, and pricing signals such as no public list prices, a roughly \u003cstrong\u003e75%\u003c\/strong\u003e recurring-sales mix, \u003cstrong\u003e25%-27%\u003c\/strong\u003e operating margins, \u003cstrong\u003e$8.35-$8.55\u003c\/strong\u003e 2026 EPS guidance, and a \u003cstrong\u003e$0.40\u003c\/strong\u003e quarterly dividend.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eDanaher Corporation - Marketing Mix: Product\u003c\/h2\u003e\n\u003cp\u003eDanaher Corporation’s product mix is built around recurring bioprocessing consumables, diagnostics analyzers and assays, and life sciences instruments. The strongest commercial feature is repeat demand: capital equipment creates the installed base, then consumables, assays, and service attach to it.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBioprocessing consumables.\u003c\/strong\u003e Cytiva and Pall supply filtration products, chromatography resins, single-use bags, tubing, connectors, and other disposable components used in biologics manufacturing. These products matter because they are consumed in each production run, so demand is tied to ongoing manufacturing activity rather than one-time equipment sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDiagnostics analyzers and assays.\u003c\/strong\u003e Danaher sells clinical analyzers, cartridges, reagents, and assay kits through businesses such as Beckman Coulter and Cepheid. The product model combines analyzer placement with recurring assay purchases, which is important in hospitals, clinical laboratories, and near-patient testing settings.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLife sciences instruments.\u003c\/strong\u003e Danaher’s life sciences portfolio includes microscopy, flow cytometry, centrifugation, sample preparation, genomics tools, and antibody and reagent products. The \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e Abcam acquisition, completed in \u003cstrong\u003e2023\u003c\/strong\u003e at \u003cstrong\u003e$24\u003c\/strong\u003e per share, added antibody and reagent depth to the research-use product set.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCytiva Fibro dT platform.\u003c\/strong\u003e This platform sits in Cytiva’s downstream purification portfolio and fits Danaher’s focus on specialized chromatography solutions for bioprocessing customers. It supports product workflows that must stay precise, repeatable, and compliant in regulated manufacturing environments.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI-enabled automation partnerships.\u003c\/strong\u003e Danaher’s product direction is moving toward connected instruments, automated workflows, and data-driven analysis that reduce manual steps in laboratories and manufacturing sites. For buyers, the value is not just the device, but the fit between instruments, software, automation, and downstream data use.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eProduct area\u003c\/th\u003e\n    \u003cth\u003eCore offerings\u003c\/th\u003e\n    \u003cth\u003eCustomer use\u003c\/th\u003e\n    \u003cth\u003eProduct logic\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eBioprocessing consumables\u003c\/td\u003e\n    \u003ctd\u003eFiltration products, chromatography resins, single-use bags, tubing, connectors\u003c\/td\u003e\n    \u003ctd\u003eBiologics manufacturing\u003c\/td\u003e\n    \u003ctd\u003eRecurring demand tied to each batch\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDiagnostics analyzers and assays\u003c\/td\u003e\n    \u003ctd\u003eAnalyzers, cartridges, reagents, assay kits\u003c\/td\u003e\n    \u003ctd\u003eClinical testing and near-patient diagnostics\u003c\/td\u003e\n    \u003ctd\u003eInstrument plus consumable pull-through\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLife sciences instruments\u003c\/td\u003e\n    \u003ctd\u003eMicroscopy, flow cytometry, centrifugation, sample preparation, genomics tools, antibody and reagent products\u003c\/td\u003e\n    \u003ctd\u003eResearch, discovery, and development\u003c\/td\u003e\n    \u003ctd\u003eBroad workflow coverage across the lab\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCytiva Fibro dT platform\u003c\/td\u003e\n    \u003ctd\u003eDownstream purification platform\u003c\/td\u003e\n    \u003ctd\u003eBioprocessing purification step\u003c\/td\u003e\n    \u003ctd\u003eSpecialized chromatography product\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAI-enabled automation partnerships\u003c\/td\u003e\n    \u003ctd\u003eConnected instruments, software-linked workflows, automated analysis\u003c\/td\u003e\n    \u003ctd\u003eLab productivity and process control\u003c\/td\u003e\n    \u003ctd\u003eLower manual work and faster data handling\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDanaher segments.\u003c\/strong\u003e The company operates through \u003cstrong\u003e3\u003c\/strong\u003e core segments: Biotechnology, Life Sciences, and Diagnostics. That structure matters because each segment sells products at different points in the customer workflow, from discovery to manufacturing to clinical testing.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eConsumables anchor repeat purchases after an instrument is installed\u003c\/li\u003e\n  \u003cli\u003eAssays and reagents create recurring revenue in diagnostics and research\u003c\/li\u003e\n  \u003cli\u003eInstruments drive customer lock-in through workflow compatibility\u003c\/li\u003e\n  \u003cli\u003eSoftware and automation raise switching costs because data, validation, and training become part of the product\u003c\/li\u003e\n  \u003cli\u003eTechnical support adds value where products are used in regulated or highly controlled environments\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eProduct-relevant event\u003c\/th\u003e\n    \u003cth\u003eAmount\u003c\/th\u003e\n    \u003cth\u003eProduct impact\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAbcam acquisition\u003c\/td\u003e\n    \u003ctd\u003e$5.7 billion\u003c\/td\u003e\n    \u003ctd\u003eExpanded antibody and reagent products\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAbcam offer price\u003c\/td\u003e\n    \u003ctd\u003e$24 per share\u003c\/td\u003e\n    \u003ctd\u003eAdded depth in research-use products\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDanaher core segments\u003c\/td\u003e\n    \u003ctd\u003e3\u003c\/td\u003e\n    \u003ctd\u003eBiotechnology, Life Sciences, Diagnostics\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eDanaher Corporation - Marketing Mix: Place\u003c\/h2\u003e\n\u003cp\u003eDanaher’s place strategy is a direct, field-service-heavy model built around hospitals, laboratories, universities, and biopharma plants. U.S. higher-education R\u0026amp;D reached \u003cstrong\u003e$108.8B\u003c\/strong\u003e in FY2023, NIH funding was \u003cstrong\u003e$47.4B\u003c\/strong\u003e in FY2024, and the U.S. had \u003cstrong\u003e6,093\u003c\/strong\u003e hospitals.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlace segment\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003eDistribution meaning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal life sciences footprint\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$108.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLarge university and translational research buying base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal diagnostics footprint\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6,093\u003c\/strong\u003e; \u003cstrong\u003e320,000+\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHospital and laboratory channel needs local service and replenishment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNorth American academic research exposure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$47.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFederal research funding keeps instruments and consumables close to campuses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal life sciences footprint\u003c\/strong\u003e: The life sciences place model depends on recurring access to research labs, core facilities, and bioprocessing sites. U.S. higher-education R\u0026amp;D at \u003cstrong\u003e$108.8B\u003c\/strong\u003e in FY2023 means a large installed base of buyers that need local application support, validation, and consumable replenishment. NIH funding of \u003cstrong\u003e$47.4B\u003c\/strong\u003e in FY2024 keeps that demand concentrated around universities, medical schools, and affiliated research centers.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eDirect sales to biopharma process development and manufacturing sites\u003c\/li\u003e\n\u003cli\u003eDirect sales to university labs, medical schools, and core facilities\u003c\/li\u003e\n\u003cli\u003eRegional stocking of consumables, reagents, and spare parts\u003c\/li\u003e\n\u003cli\u003eOn-site installation, qualification, and service\u003c\/li\u003e\n\u003cli\u003eDistributor coverage for smaller and mid-sized accounts\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal diagnostics footprint\u003c\/strong\u003e: Diagnostics place coverage is strongest where testing volume is concentrated. The U.S. had \u003cstrong\u003e6,093\u003c\/strong\u003e hospitals and more than \u003cstrong\u003e320,000\u003c\/strong\u003e CLIA-certified laboratories, so access depends on field service, instrument uptime, and reagent availability rather than retail shelves. That channel structure favors local technical teams and short replenishment cycles.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics access point\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003ePlace requirement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6,093\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInstalled instruments, service response, and uptime\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCLIA-certified laboratories\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e320,000+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh-frequency consumables and maintenance visits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic research funding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$47.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGrant-linked procurement and budget timing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrong China bioprocessing demand\u003c\/strong\u003e: China matters because bioprocessing customers usually buy through local technical sales teams, validation support, and fast service response. For Danaher, the place decision is about being close to manufacturing clusters and keeping installation, qualification, and maintenance on the customer’s side of the supply chain.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNorth American academic research exposure\u003c\/strong\u003e: North American demand is tied to public research money and campus procurement cycles. With \u003cstrong\u003e$108.8B\u003c\/strong\u003e in U.S. higher-education R\u0026amp;D in FY2023 and \u003cstrong\u003e$47.4B\u003c\/strong\u003e in NIH funding in FY2024, Danaher’s products need to be positioned near universities, medical schools, and shared research facilities where purchasing is driven by grants and lab budgets.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBiopharma reshoring markets\u003c\/strong\u003e: Reshoring shifts demand toward domestic plants, validation labs, and U.S. service depots. That makes local inventory, installation teams, and field service more important because process equipment and diagnostics platforms are typically validated site by site, not moved through consumer-style distribution.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eDanaher Corporation - Marketing Mix: Promotion\u003c\/h2\u003e\n\u003cp\u003eDanaher’s promotion is built around \u003cstrong\u003e3\u003c\/strong\u003e public signals: product launch announcements, FDA clearance messaging, and partner announcements. The company reported \u003cstrong\u003e$23.9 billion\u003c\/strong\u003e of revenue in \u003cstrong\u003e2023\u003c\/strong\u003e, and that scale helps those messages reach buyers across Diagnostics, Life Sciences, and Biotechnology.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePromotion area\u003c\/th\u003e\n\u003cth\u003eReal-life numeric marker\u003c\/th\u003e\n\u003cth\u003ePublic message type\u003c\/th\u003e\n\u003cth\u003ePromotion role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct launch announcements\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e segments\u003c\/td\u003e\n\u003ctd\u003eLaunch release\u003c\/td\u003e\n\u003ctd\u003eOne message across Biotechnology, Life Sciences, and Diagnostics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA clearance messaging\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e510(k)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRegulatory notice\u003c\/td\u003e\n\u003ctd\u003eRegulatory proof point inside the sales message\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstraZeneca diagnostics partnership\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e-party collaboration\u003c\/td\u003e\n\u003ctd\u003ePartner announcement\u003c\/td\u003e\n\u003ctd\u003eNo public dollar amount disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomata automation partnership\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e-party collaboration\u003c\/td\u003e\n\u003ctd\u003ePartner announcement\u003c\/td\u003e\n\u003ctd\u003eNo public dollar amount disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDBS operational branding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1984\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOperating system message\u003c\/td\u003e\n\u003ctd\u003eCommon operating language across the group\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany scale\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.9 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023 revenue\u003c\/td\u003e\n\u003ctd\u003eSupports broad B2B promotion reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eProduct launch promotion at Danaher is tied to one named product, one buyer group, and one segment message. The company uses launch releases across \u003cstrong\u003e3\u003c\/strong\u003e operating segments, so the same public-relations format can cover an instrument, an assay, or an automation platform. In B2B healthcare and lab markets, that matters because the launch message is part of the buying process, not just a news item. The company’s \u003cstrong\u003e$23.9 billion\u003c\/strong\u003e of 2023 revenue shows the scale behind that launch cadence.\u003c\/p\u003e\n\n\u003cp\u003eFDA clearance messaging is a core promotion tool because the headline itself can carry the code \u003cstrong\u003e510(k)\u003c\/strong\u003e or \u003cstrong\u003eEUA\u003c\/strong\u003e. Those pathways are not marketing language; they are regulatory labels that become part of the sales story. For diagnostics customers, the clearance code often comes before price, throughput, or turnaround time in the decision process. That is why Danaher’s promotion frequently uses the FDA result as the first proof point in the public announcement.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e510(k)\u003c\/strong\u003e signals FDA device clearance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEUA\u003c\/strong\u003e signals emergency use authorization.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e segment-level messages help separate Diagnostics, Life Sciences, and Biotechnology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e revenue of \u003cstrong\u003e$23.9 billion\u003c\/strong\u003e supports wide distribution of launch messaging.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe AstraZeneca diagnostics partnership follows a \u003cstrong\u003e2\u003c\/strong\u003e-party credibility model. The public message is the collaboration itself, and no public dollar amount was disclosed. That matters in diagnostics because a partner announcement can support clinical confidence and market access without disclosing contract value. In academic writing, this is a clear example of promotion through external validation rather than paid advertising.\u003c\/p\u003e\n\n\u003cp\u003eThe Automata automation partnership uses the same structure: \u003cstrong\u003e2\u003c\/strong\u003e companies, one automation message, and no public dollar amount disclosed. For Danaher, this type of promotion is about workflow credibility, lab automation, and fewer manual steps. The value of the announcement is not only the product link; it is the signal that Danaher’s automation story is connected to another specialized operator in the market.\u003c\/p\u003e\n\n\u003cp\u003eDanaher Business System (DBS), started in \u003cstrong\u003e1984\u003c\/strong\u003e, is part of the company’s promotional identity because it gives every subsidiary the same operating language. When Danaher talks about quality, speed, or continuous improvement, DBS makes those claims consistent across \u003cstrong\u003e3\u003c\/strong\u003e segments. That consistency matters because a hospital lab, a biotech customer, and a research buyer all hear the same operating message even when the product line differs.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eDanaher Corporation - Marketing Mix: Price\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003ePublic list prices:\u003c\/strong\u003e not disclosed.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRecurring-sales mix:\u003c\/strong\u003e roughly \u003cstrong\u003e75%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOperating margins:\u003c\/strong\u003e \u003cstrong\u003e25%\u003c\/strong\u003e to \u003cstrong\u003e27%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e2026 EPS guidance:\u003c\/strong\u003e \u003cstrong\u003e$8.35\u003c\/strong\u003e to \u003cstrong\u003e$8.55\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQuarterly dividend:\u003c\/strong\u003e \u003cstrong\u003e$0.40\u003c\/strong\u003e per share.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAnnualized dividend run rate:\u003c\/strong\u003e \u003cstrong\u003e$1.60\u003c\/strong\u003e per share.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEPS guidance midpoint:\u003c\/strong\u003e \u003cstrong\u003e$8.45\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003ePrice item\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eNumber or amount\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eFiled or disclosed status\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePublic list prices\u003c\/td\u003e\n    \u003ctd\u003eNot disclosed\u003c\/td\u003e\n    \u003ctd\u003eNot publicly listed\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRecurring-sales mix\u003c\/td\u003e\n    \u003ctd\u003eRoughly 75%\u003c\/td\u003e\n    \u003ctd\u003eDisclosed operating mix\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOperating margin\u003c\/td\u003e\n    \u003ctd\u003e25% to 27%\u003c\/td\u003e\n    \u003ctd\u003eDisclosed target range\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2026 EPS guidance\u003c\/td\u003e\n    \u003ctd\u003e$8.35 to $8.55\u003c\/td\u003e\n    \u003ctd\u003eDisclosed guidance range\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQuarterly dividend\u003c\/td\u003e\n    \u003ctd\u003e$0.40 per share\u003c\/td\u003e\n    \u003ctd\u003eDeclared cash dividend\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAnnualized dividend\u003c\/td\u003e\n    \u003ctd\u003e$1.60 per share\u003c\/td\u003e\n    \u003ctd\u003e$0.40 x 4\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eEPS midpoint\u003c\/td\u003e\n    \u003ctd\u003e$8.45\u003c\/td\u003e\n    \u003ctd\u003e($8.35 + $8.55) \/ 2\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e75%\u003c\/strong\u003e recurring-sales mix\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e25%\u003c\/strong\u003e to \u003cstrong\u003e27%\u003c\/strong\u003e operating margins\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$8.35\u003c\/strong\u003e to \u003cstrong\u003e$8.55\u003c\/strong\u003e 2026 EPS guidance\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$0.40\u003c\/strong\u003e quarterly dividend per share\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$1.60\u003c\/strong\u003e annualized dividend per share\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44602210025621,"sku":"dhr-marketing-mix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/dhr-marketing-mix.png?v=1740165613","url":"https:\/\/dcf-analysis.com\/products\/dhr-marketing-mix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}